Develops gene therapies that deliver targeted genetic treatments for chronic and complex diseases.
Buy
Sign up to view historical trading trends and place an offer.
Sell
Understand share pricing, list anonymously, and benefit from transparent fees.
Overview
Kriya Therapeutics develops gene therapies designed to treat chronic and complex diseases. The company engineers genetic medicines that deliver therapeutic genes to target tissues to address underlying causes of disease. Its platform focuses on scalable manufacturing and precision delivery to improve treatment effectiveness.
Buy
Sign up to view historical trading trends and place an offer.
Sell
Understand share pricing, list anonymously, and benefit from transparent fees.
Investors
Woodline Partners
Foresite Capital
Patient Square Capital
Transhuman Capital
JDRF T1D Fund
Amplo
CAM Capital
Dexcel Pharma
Narya Capital
QVT Financial LP
Lightswitch Capital
Bluebird Ventures
Premji Invest
Alumni Ventures Group
Kriya Therapeutics Valuations & Financials
View real-time NPM data on Kriya Therapeutics stock including daily Kriya Therapeutics stock price estimates, valuation history, and historical share price information. Access Kriya Therapeutics financing rounds, secondary trade levels, cap table data, and private company comparable transactions. Use NPM's private company valuation database to track Kriya Therapeutics pricing across six independent market signals. Looking for private company due diligence data sources on Kriya Therapeutics? Get in touch to learn more.
Similar Companies
like Kriya Therapeutics
Cerebral
Healthcare & Life Sciences
Telemedicine mental health startup, providing evidence-based therapeutic techniques and medication management.
Eikon Therapeutics
Healthcare & Life Sciences
Uses revolutionary technology to discover novel treatments for life-threatening diseases.
Moximed
Healthcare & Life Sciences
Implantable Shock Absorbers for Knee osteoarthritis.
Commure
Healthcare & Life Sciences
Development platform for health systems, vendors and startups to build healthcare applications and software.
Mammoth Biosciences
Healthcare & Life Sciences
Developed a CRISPR-based platform for disease to enable the detection of any type of nucleic acid.
Paradigm
Healthcare & Life Sciences
Optimizes drug development through data-driven solutions and advanced technology to streamline clinical trials and enhance decision-making.
Akston Biosciences
Healthcare & Life Sciences
Develops and manufactures protein-based therapeutics for pets using proprietary technology to create species-specific medical treatments.
FAQ
We have answers
Kriya Therapeutics stock does not trade on public stock exchanges. Kriya Therapeutics stock is considered a private security and you need to be an accredited investor to trade shares. To invest in Kriya Therapeutics stock you can either buy shares directly through the company or work with a secondary trading marketplace like Nasdaq Private Market.
Learn more about the secondary market for private company shares on the investors page.
Kriya Therapeutics Stock does not trade on public stock exchanges. In order to sell Kriya Therapeutics shares you need to work directly with the company or with a secondary trading marketplace like Nasdaq Private Market. NPM has more than a decade of experience helping sell shares on the private market to our network of institutional investors.
Learn more about NPM services for selling privately held stock on the Employee Shareholders page.
Read more about how to sell private company stock on the private secondary market:
Kriya Therapeutics does not have a publicly available stock price because it is privately held and not traded on public stock exchanges. Through the NPM Data and Intelligence database from Nasdaq Private Market, you can view Kriya Therapeutics share price and other valuable private market data.
Read more about secondary market private company stock prices:
There is no ticker symbol for Kriya Therapeutics stock because it is a private company. Private companies do not have ticker symbols like public companies, they are identified primarily by using the company ‘street’ name or legal name.
Nasdaq Private Market currently works with employees, ex-employees, and other company investors. In order to sell Kriya Therapeutics stock you need to receive the company’s approval, which Nasdaq Private Market manages on your behalf.
Learn more about selling privately held stock on the Employee Shareholders page.
Read more about how to sell shares of a private company and eligibility for selling privately held stock:
Currently, Nasdaq Private Market only works with accredited entities and institutional investors to purchase private company stock. In order to invest in Kriya Therapeutics stock, you need to be an accredited entity or institutional investor.
Learn more about the Nasdaq Private Market tool kit for investors on the Investor Trading page.
Once you buy or sell, stock share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patent-pending Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.
To learn more about private company stock Transfer and Settlement, check out the Transfer and Settlement page.
Kriya Therapeutics is a private company and has not had an IPO. There is currently no Kriya Therapeutics IPO price. Get started to begin exploring the Nasdaq Private Market Data and Intelligence database and gain access to actionable data related to Kriya Therapeutics IPO.
Learn more about Data and Intelligence private company stock data for institutional investors on the on the NPM Data and Intelligence Product Page.
